Note 8 - Shareholders' Equity

9 Months Ended

Nov. 25, 2018

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

8

.

SHAREHOLDERS’ EQUITY

During the

39

weeks ended

November 25, 2018,

the Company sold

37,837

shares of the Company’s treasury stock pursuant to the exercises of employee stock options and received proceeds of

$661

from such exercises. The Company recognized stock-based compensation expense, net of tax benefits, of

$594.

On

January 8, 2015,

the Company announced that its Board of Directors authorized the Company’s purchase, on the open market and in privately negotiated transactions, of up to

1,250,000

shares of its common stock, representing approximately

6%

of the Company’s

20,945,634

total outstanding shares as of the close of business on

January 7, 2015.

This authorization superseded all prior Board of Directors’ authorizations to purchase shares of the Company’s common stock.

On

March 10, 2016,

the Company announced that its Board of Directors authorized the Company’s purchase, on the open market and in privately negotiated transactions, of up to

1,000,000

additional shares of its common stock, in addition to the unused prior authorization to purchase shares of the Company’s common stock announced on

January 8, 2015.

As a result, the Company is authorized to purchase up to a total of

1,531,412

shares of its common stock, representing approximately

7.6%

of the Company’s

20,279,408

total outstanding shares as of the close of business on

January 3, 2019.

The Company did

not

purchase any shares of its common stock during the

39

weeks ended

November 25, 2018

or during the

39

weeks ended

November 26, 2017.